Term
HMG CoA reductase inhibitors |
|
Definition
Lovastatin & other -statins: MOA: inhibits the rate limiting enzyme in cholesterol synthesis (dec. liver cholesterol & plasma LDL but inc. LDL receptor expression) Decrease in VLDL synthesis resuls in dec. TG's too SE: myalgia, myopathy, rhabdomyolysis, hepatotoxicity (check LFT's) DI: Gemfibrozil (increases rhabdomyolysis) P450 inhibitors enhance toxicity |
|
|
Term
|
Definition
Cholestyramine & colestipol MOA: prevent recycling of bile salts in the gut which dec. liver's recirculation of bile salts so the liver has to make new each time (overall dec. liver cholesterol and blood cholesterol but inc. LDL receptor expression) SE: increases VLDL and TG's, GI disturbances, malabsorption of lipid-soluble vitamins DI: w/ orally administered warfarin, thiazides, dig Contraindication: w/ hypertriglyceridemia |
|
|
Term
|
Definition
Niacin & Vitamin B3 MOA: inhibition of VLDL synthesis so decreases plasma VLDL/LDL and increases HDL SE: flushing, pruritits (pretreat w/ ASA) hepatotoxicity |
|
|
Term
Gemfibrozil (fenofibrate) |
|
Definition
MOA: activation of lipoprotein lipases (dec. VLDL/IDL w/ modest decrease in LDL but increases HDL) used in pts w/ hypertriglyceridemia SE: May actually increases LDL in some Gallstones, myositis |
|
|
Term
|
Definition
MOA: prevents intestinal absorption of cholesterol results in dec. LDL SE: GI distress |
|
|
Term
Pts w/ only high cholesterol (meds to use) |
|
Definition
Cholestyramine, colestipol, ezetimibe |
|
|
Term
|
Definition
|
|
Term
Pts w/ high cholesterol and high TG's |
|
Definition
Statins, niacin, ezetimibe |
|
|